Last reviewed · How we verify
NCT05483790
The Effects of Multidomain Non-pharmacological Interventions on the Elderly With or Without Mild Cognitive Impairment
NA trial testing the multimodal intervention in Mild Cognitive Impairment in 120 participants. Completed in 31 December 2024.
31 December 2024
Quick facts
| Lead sponsor | Huashan Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 120 |
| Start date | 1 June 2020 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- the multimodal intervention
Conditions studied
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
- The Cognitive Normal Elderly — all drugs for The Cognitive Normal Elderly →
Sponsor
Huashan Hospital
Who can join
Adults 50 to 75, any sex, with Mild Cognitive Impairment or The Cognitive Normal Elderly. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aiming to investigate the efficacy, safety, and potential mechanism of a multimodal intervention on cognitive function in individuals with MCI or the cognitive normal elderly living in a community. The recruited elderly aged 50-75 years with normal cognitive function or MCI will be divided into the intervention group or the control group randomly. The intervention group will be accepted a multidimensional non-pharmacological intervention (cognitive training, physical exercise, healthy lifestyle intervention, and computerized interaction training) while the control group receives health education. Sociodemographics will be collected before the intervention. comprehensive neuropsychological tests and MRI will be collected before and 6 weeks, 12 weeks, 3 months, 6 months, 12 months after the randomization respectively.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05483790
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting
Other Huashan Hospital trials
Trials by the same sponsor.
- NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
- NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
- NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
- NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
- NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05483790 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
- Last refreshed: 15 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05483790.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing